Multidrug Tolerance of Biofilms and Persister Cells
Bacterial populations produce a small number of dormant persister cells that exhibit multidrug tolerance. All resistance mechanisms do essentially the same thing: prevent the antibiotic from hitting a target. By contrast, tolerance apparently works by shutting down the targets. Bactericidal antibiotics kill bacteria by corrupting their targets, rather than merely inhibiting them. Shutting down the targets then protects from killing. The number of persisters in a growing population of bacteria rises at mid-log and reaches a maximum of approximately 1% at stationary state. Similarly, slow-growing biofilms produce substantial numbers of persisters. The ability of a biofilm to limit the access of the immune system components, and the ability of persisters to sustain an antibiotic attack could then account for the recalcitrance of such infections in vivo and for their relapsing nature. Isolation of Escherichia coli persisters by lysing a population or by sorting GFP-expressing cells with diminished translation allowed to obtain a gene expression profile. The profile indicated downregulated biosynthetic pathways, consistent with their dormant nature, and indicated overexpression of toxin/antitoxin (TA) modules. Stochastic overexpression of toxins that inhibit essential functions such as translation may contribute to persister formation. Ectopic expression of RelE, MazF, and HipA toxins produced multidrug tolerant cells. Apart from TA modules, glpD and plsB were identified as potential persister genes by overexpression cloning of a genomic library and selection for antibiotic tolerance. Yeast Candida albicans forms recalcitrant biofilm infections that are tolerant to antibiotics, similarly to bacterial biofilms. C. albicans biofilms produce multidrug tolerant persisters that are not mutants, but rather phenotypic variants of the wild type. Unlike bacterial persisters, however, C. albicans persisters were only observed in a biofilm, but not in a planktonic stationary population. Identification of persister genes opens the way to a rational design of anti-biofilm therapy. Combination of a conventional antibiotic with a compound inhibiting persister formation or maintenance may produce an effective therapeutic. Other approaches to the problem include sterile-surface materials, prodrug antibiotics, and cyclical application of conventional antimicrobials.
KeywordsAtom Transfer Radical Polymerization Antimicrob Agent Persister Cell Persister Formation Persister Gene
Unable to display preview. Download preview PDF.
- Denyer SP, Hugo WB (1991) Mechanisms of action of chemical biocides: their study and exploitation. Society for Applied BacteriologyGoogle Scholar
- Hooper DC (2002) Target modification as a mechanism of antimicrobial resistance. In: Lewis K, Salyers A, Taber H and Wax R (eds) Bacterial resistance to antimicrobials: mechanisms genetics medical practice and public health. Marcell Dekker, New York, pp 161–192Google Scholar
- Lewis K, Lomovskaya O (2002) Drug efflux. In: Lewis K, Salyers A, Taber H and Wax R (eds) Bacterial resistance to antimicrobials: mechanisms genetics medical practice and public health. Marcel Dekker, New York, pp 61–90Google Scholar
- Lewis K, Salyers A, Taber H, Wax R (2002) Bacterial resistance to antimicrobials: mechanisms genetics medical practice and public health. Marcel Dekker, New YorkGoogle Scholar
- Lewis K, Spoering A, Kaldalu N, Keren I, Shah D (2005) Persisters: specialized cells responsible for biofilm tolerance to antimicrobial agents. In: Pace J, Rupp ME and Finch RG (eds) Biofilms infection, and antimicrobial therapy. Taylor & Francis, Boca Raton, pp 241–256Google Scholar
- Mack D, Becker P, Chatterjee I, Dobinsky S, Knobloch JK, Peters G, Rohde H, Herrmann M (2004) Mechanisms of biofilm formation in Staphylococcus epidermidis and Staphylococcus aureus: functional molecules, regulatory circuits, and adaptive responses. Int J Med Microbiol 294:203–212PubMedCrossRefGoogle Scholar
- Morgan HC, Meier JF, Merker RL (2000) Method of creating a biostatic agent using interpenetrating network polymers. US Patent No. 6, 146, 688Google Scholar
- Osburne MS, Grossman TH, August PR, MacNeil IA (2000) Tapping into microbial diversity for natural products drug discovery. ASM News 66:411–417Google Scholar
- Schatz A, Bugie E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 55:66–69Google Scholar
- Walker GC (1996) The SOS response of Escherichia coli. In: Neidhardt FC (ed) Escherichia coli and Samonella. Cellular and molecular biology. ASM Press, Washington DC, pp 1400–1416Google Scholar
- Walsh C (2003a) Antibiotics. Actions, origins, resistance. ASM Press, Washington DCGoogle Scholar